(12) **Translation of European patent specification**

(11) **NO/EP 3004155 B1**

NORWAY

(19) NO

(51) Int Cl.
A61P 3/04 (2006.01)
A61K 38/00 (2006.01)
A61P 3/10 (2006.01)
A61P 43/00 (2006.01)
C07K 14/605 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.01.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.11.24
(86)	European Application Nr.	14729976.2
(86)	European Filing Date	2014.05.27
(87)	The European Application's Publication Date	2016.04.13
(30)	Priority	2013.05.28, JP, 2013111893
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-chome Chuo-ku, Osaka-shi, Osaka 541-0045, Japan
(72)	Inventor	ASAMI, Taiji, Fujisawa Kanagawa 251-0012, Japan NIIDA, Ayumu, Fujisawa Kanagawa 251-0012, Japan
(74)	Agent or Attorney	Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark

(54) Title **PEPTIDE COMPOUND**

(56) References Cited:

WO-A2-2012/088379
WO-A2-2010/011439
AL-SABAH SULEIMAN ET AL: "A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, HANTS; GB, vol. 140, no. 2, 1 September 2003 (2003-09-01), pages 339-346, XP002437826, ISSN: 0007-1188, DOI: 10.1038/SJ.BJP.0705453
STEFFEN RUNGE ET AL: "Differential Structural Properties of GLP-1 and Exendin-4 Determine Their Relative Affinity for the GLP-1 Receptor N-Terminal Extracellular Domain +", BIOCHEMISTRY, vol. 46, no. 19, 1 May 2007 (2007-05-01), pages 5830-5840, XP055138608, ISSN: 0006-2960, DOI: 10.1021/bi062309m

Patentkrav

1. Peptid valgt fra
H-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Ala-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH_2 eller et salt derav,
H-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-Aib-Ile-Aib-Leu-Asp-Lys-Gln-Ala-Gln-Ala-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH_2 eller et salt derav,
H-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Gln-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH_2 eller et salt derav, og
H-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Gln-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH_2 eller et salt derav.

2. Peptidet eller saltet ifølge krav 1, som er H-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Ala-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH_2 eller et salt derav.

3. Peptidet eller saltet ifølge krav 1, som er H-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-Aib-Ile-Aib-Leu-Asp-Lys-Gln-Ala-Gln-Ala-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH_2 eller et salt derav.

4. Peptidet eller saltet ifølge krav 1, som er H-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Gln-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH_2 eller et salt derav.

5. Peptidet eller saltet ifølge krav 1, som er H-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Gln-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH_2 eller et salt derav.

6. Medikament omfattende peptidet ifølge krav 1 eller et salt derav.

7. Medikamentet ifølge krav 6, for anvendelse i profylaksen eller behandlingen av fedme eller diabetes.

8. Peptidet ifølge krav 1 eller et salt derav for anvendelse i profylaksen eller behandlingen av fedme eller diabetes.

9. Sammensetning omfattende peptidet ifølge krav 1 eller et salt derav og et ledsagende legemiddel.